Highlights From ASCO-SITC

Beyond PD-1: Harnessing Receptor Crosstalk to Overcome Immune Escape
Highlights From ASCO-SITC, Highlights From ASCO
Best Practices in Immunotherapy – June/July 2017 Vol 8
Immune checkpoint therapy, specifically PD-1 blockade, has improved survival for patients with metastatic cancer, but not all patients respond to treatment.

Page 2 of 2

Journal of Oncology Navigation & Survivorship

Connect with Us

 
 

Contact Us | Editorial Board

Amplity

© Amplity, Inc. All rights reserved.

JONS

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
    Profession or Role
    Primary Specialty or Disease State
    Country

Back to Top

Amplity © Amplity, Inc. All rights reserved.

We Value Your Feedback! Tell Us How You Consume Content

Your feedback will help us tailor our content to better meet your needs and preferences.

*First Name
*Last Name
*Email
*What's your favorite format for experiencing our content?